Martek sales stable, inventory destocking looms
This article was originally published in The Tan Sheet
Executive SummaryThe maker of life'sDHA reports second quarter revenues inched up 1.9 percent to $92.4 million, despite a 1.3 percent dip in infant formula sales to $77.4 million. Martek Biosciences set records for revenues and pretax profits during the quarter ended April 30, reporting 19.7 percent growth in net income to $11 million over the year-ago period. The Columbia, Md.-based nutritional oils firm said during a June 3 earnings call it expects a $10 million to $15 million revenue hit due to destocking of infant formula during its fiscal 2009 third and fourth quarters. CEO Steve Dubin expects the destocking to be temporary and infant formula sales growth should resume in 2010
You may also be interested in...
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.